Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
3.
Lakartidningen ; 96(7): 722-5, 1999 Feb 17.
Artículo en Sueco | MEDLINE | ID: mdl-10087774

RESUMEN

The past few years have witnessed encouraging progress in experimental HIV vaccination. Several new vaccine candidates have been shown to elicit immune response and provide protection in animals, and the first immunotherapy trials in humans have been reported. Difficulties remain to be overcome, however. No consensus exists regarding trials in humans. Some researchers and clinicians believe that we must await a vaccine demonstrably and reproducibly effective in animals. Immunogenicity alone is considered insufficient to ensure clinical protection. Others consider animal experiments valuable, but believe that actual trials should be made in humans in the target population. Trials are urgently needed in countries with high transmission rates, even if optimal efficacy cannot be guaranteed.


Asunto(s)
Infecciones por VIH/prevención & control , Vacunas de ADN/provisión & distribución , Vacunas Virales/provisión & distribución , Animales , Humanos , Receptores del VIH/genética , Receptores del VIH/inmunología , Vacunas Atenuadas/administración & dosificación , Vacunas Atenuadas/provisión & distribución , Vacunas de ADN/administración & dosificación , Vacunas Virales/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA